

**Title: Transcriptome network analysis implicates CX3CR1-positive type 3 dendritic cells in non-infectious uveitis**

**Authors:**

S. Hiddingh<sup>1,3†</sup>, A. Pandit<sup>3,4†</sup>, F.H. Verhagen<sup>1-3†</sup>, R. Rijken<sup>3,4</sup>, N. H. Servaas<sup>3,4</sup>, C.G.K. Wicher<sup>3,4</sup>, N.H. ten Dam-van Loon<sup>2</sup>, S.M. Imhof<sup>1,2</sup>, T.R.D.J. Radstake<sup>5‡</sup>, J.H. de Boer<sup>1,2‡</sup>, J.J.W. Kuiper<sup>1-3‡\*</sup>

**Affiliations:**

<sup>1</sup> Ophthalmic Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

<sup>2</sup> Department of Ophthalmology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

<sup>3</sup> Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

<sup>4</sup> Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

<sup>5</sup> University Medical Center Utrecht and Utrecht University, Utrecht, The Netherlands and AbbVie, Chicago, IL.

\* these authors contributed equally,

† these authors contributed equally.

\* Corresponding author:

J.J.W. Kuiper [J.J.W.Kuiper@umcutrecht.nl](mailto:J.J.W.Kuiper@umcutrecht.nl) Heidelberglaan 100, 3584CX, Utrecht, The Netherlands.

## ABSTRACT

**Background:** Type I interferons (IFNs) promote the expansion of subsets of CD1c+ conventional dendritic cells (CD1c+ DCs), but the molecular basis of CD1c+ DCs involvement in conditions not associated without elevated type I IFNs remains unclear.

**Methods:** We analyzed CD1c+ DCs from two cohorts of non-infectious uveitis patients and healthy donors using RNA-sequencing followed by high-dimensional flow cytometry to characterize the CD1c+ DC populations.

**Results:** We report that the CD1c+ DCs pool from patients with non-infectious uveitis is skewed towards a gene module with the chemokine receptor CX3CR1 as the key hub gene. We confirmed these results in an independent case-control cohort and show that the disease-associated gene module is not mediated by type I IFNs. An analysis of peripheral blood using flow cytometry revealed that CX3CR1+ DC3s were diminished, whereas CX3CR1- DC3s were not. Stimulated CX3CR1+ DC3s secrete high levels of inflammatory cytokines, including TNF-alpha, and CX3CR1+ DC3-like cells can be detected in inflamed eyes of patients.

**Conclusions:** These results show that CX3CR1+ DC3s are implicated in non-infectious uveitis and can secrete proinflammatory mediators implicated in its pathophysiology.

**Funding:** The presented work is supported by UitZicht (project number #2014-4, #2019-10, an #2021-4). The funders had no role in the design, execution, interpretation, or writing of the study.

## INTRODUCTION:

Non-infectious uveitis refers to a group of chronic inflammatory eye diseases that are among the leading causes of preventable vision loss in western countries (1,2). Currently, little is known about the disease mechanism of non-infectious uveitis. A large body of mechanistic studies using experimental autoimmune uveitis (EAU) in rodents suggest that T cells play a role in non-infectious uveitis (3,4). Human non-infectious uveitis is characterized by inflammation and T cells infiltrating the eyes through unknown mechanisms. The genetic association between non-infectious uveitis and *MHC*, and *ERAP1*, *ERAP2* genes indicates that antigen presentation is central to the etiology (5-8). A key antigen presenting cell type are dendritic cells. Despite their important role in EAU, dendritic cells have yet to be fully investigated in human non-infectious uveitis (9-11). CD1c-positive conventional dendritic cells (CD1c+ DCs) have been found to be associated with disease activity (12-14), and are abundant in eye fluid of patients (15). In order to understand the role of CD1c+ DCs in non-infectious uveitis, it is necessary to understand their functions.

Several single-cell studies have revealed that the CD1c+ DCs (and its murine equivalent, termed "cDC2s") consists of multiple subsets derived from distinct progenitors (16-18). The type I Interferon (IFN) family of cytokines promotes the expansion of a subset of CD1c+ DCs called "DC3" (17,19,20). DC3s are increased in blood of type I IFN-driven *systemic lupus erythematosus* (SLE) patients (17). A significant difference between non-infectious uveitis and SLE is that active uveitis is accompanied by lower levels of type I IFN (21, 22). It should be noted that although type I interferons can induce lupus-like disease, they can also suppress non-infectious uveitis (21, 23, 24), pointing to an alternative disease mechanism implicating CD1c+ DCs in non-infectious uveitis. Hence, we do not fully understand the characteristics of CD1c+ DC during autoimmunity, especially in conditions not driven by type I IFNs.

For the purpose of characterizing the core transcriptional features and subset composition of CD1c+ DCs in autoimmunity of the eye, we used whole transcriptome profiling by bulk RNA-

sequencing of peripheral blood CD1c+ DCs and multiparameter flow cytometry of two cohorts of non-infectious uveitis patients and healthy donors. We constructed co-expression networks that identified a robust gene module associated with non-infectious uveitis in patients that helped identify a CX3CR1-positive CD1c+ DC subset.

## MATERIAL AND METHODS

### *Patients and patient material*

This study was conducted in compliance with the Helsinki principles. Ethical approval was requested and obtained from the Medical Ethical Research Committee in Utrecht (METC protocol number #14-065/M). All patients signed written informed consent before participation. We collected blood from a discovery cohort of 29 and a replication cohort of 22 adult patients (**Table 1**) with HLA-B27-associated Acute Anterior Uveitis (AU), Idiopathic Intermediate Uveitis (IU), or HLA-A29-associated Birdshot Uveitis (BU). Patients were recruited at the outbound patient clinic of the department of Ophthalmology of the University Medical Center Utrecht between July 2014 and January 2017. We recruited twenty-nine age and sex matched anonymous blood donors of European Ancestry with no history of ocular inflammatory disease at the same institute to serve as unaffected controls (**Table 1**). Uveitis was classified and graded in accordance with the SUN classification (25). Each patient underwent a full ophthalmological examination by an ophthalmologist experienced in uveitis, routine laboratory screening, and an X-Ray of the lungs. Laboratory screening included erythrocyte sedimentation rate, renal and liver function tests, angiotensin converting enzyme (ACE), and screening for infectious agents in the serum and an Interferon-Gamma Release Assay (IGRA) was obtained for all patients. All patients with AU and BU were HLA-B27 or HLA-A29-positive, respectively (confirmed by HLA typing). All patients had active uveitis (new onset or relapse) and there was no clinical evidence for uveitis-associated systemic inflammatory disease (e.g., rheumatic condition) till the time of sampling. None of the patients received systemic immunomodulatory treatment in the last 3 months, other than low dose ( $\leq 10$ mg) oral prednisolone in one BU patient of cohort II and one AU patient of cohort I.

### *CD1c+ DC purification*

Peripheral blood mononuclear cells (PBMCs) were isolated by standard ficoll density gradient centrifugation from 70mL heparinized blood immediately after blood withdrawal (GE Healthcare, Uppsala, Sweden). For the first cohort, ten batches (individual days) of 4-5 randomly selected patient and control samples of nitrogen stored PBMCs (mean storage time of 11 [range 0-31] months) were carefully thawed and subjected to sorting by the BD FACSaria™ III sorter after incubation with a panel of surface antibodies (**Supplementary File 1A**) and FACS buffer (1% bovine serum albumin and 0.1% sodium azide in phosphate buffered saline). CD3-CD19-CD56-CD14-HLA-DR+CD11c+CD1c cells were sorted. The average number of collected cells by sorting was 56,881 (range 6,669-243,385). For the second cohort, fresh PBMCs were immediately subjected to magnetic-activated cell sorting (MACS) for the removal (positive selection) of CD304+ cells (pDC), followed by the removal of CD19+ cells (B cell), and subsequently isolation of CD1c+ cells by using the CD1c+ (BDCA1) isolation kit (Miltenyi Biotec, Germany) according to the manufacturer's instructions. The isolated CD1c+ fraction contained on average 147,114 cells (range 46,000-773,000) and purity was determined by flow cytometry (**Supplementary File 1B**) measured on the BD LSRFortessa Cell analyzer (**Figure 1 – Figure Supplement 1**). Data were analyzed using FlowJo software (TreeStar Inc.). MACS or FACS purified CD1c+ cells were immediately taken up in a lysis buffer (RLT plus, Qiagen) containing 1%  $\beta$ -mercaptoethanol, snap frozen on dry ice, and stored at -80°C until RNA extraction was performed. Isolation of CD1c+ DC for functional experiments was done by MACS as described above. Purification of CD1c+ DC subsets based on CD36 and CX3CR1 or CD14 expression from freshly isolated PBMCs was conducted by flow cytometry using the panel in **Supplementary File 1C** and shown in **Figure 3 – Figure Supplement 2B**.

### *CD1c+ DC cultures and secretome analysis.*

Purified CD1c+ DCs were cultured in RPMI Glutamax (Thermo Fisher Scientific) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Biowest Riverside) and 1% penicillin/streptomycin (Thermo Fisher Scientific). CD1c+ DCs were cultured at a concentration of  $0.5 \times 10^6$  cells/mL in a 96-well round-bottom plate (100 $\mu$ L/well). Cells were stimulated overnight (18 hours) with multiple stimuli listed in **Supplementary File 1D**. After stimulation, cells were lysed in an *RLT plus* lysis buffer (Qiagen) and stored at -80°C until RNA extraction was performed. Cell lysates were stored at -80°C until RNA extraction was performed for qPCR. In separate cultures, CD1c+ DC subsets (sorted based on CD36 and CX3CR1 expression) were cultured in the presence of 1 $\mu$ g/mL lipoteichoic acid (LTA). After 18 hours of stimulation, supernatants were harvested and IL-23 cytokine production was analyzed by ELISA (R&D Systems). The levels of IL-2, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL-17, IL-22, IL-27, TNF-alpha, IFN-alpha, IFN-beta, CCL1, CXCL10, CXCL13, VEGF, CD40L, FAS, TNFR1, TNFR2, Elastase, and Granzyme B were simultaneously measured in supernatant of CD1c+ DC cultures using the in-house multiplex immunoassay based on Luminex technology, as described previously (26). Protein concentrations that were out of range were replaced with the LLOQ (lower limit of quantification) and ULOQ (upper limit of quantification) for each analyte and divided by 2 for the proteins detected below the range of detection or multiplied by 2 for values above the detection range (**Supplementary File 1E**).

#### *Real-time Quantitative PCR*

First-strand cDNA was synthesized from total RNA using Superscript IV kit (Thermo Fisher Scientific), and quantitative real-time PCR (RT-qPCR) was performed on the QuantStudio 12k flex System (LifeTechnologies), following manufacturer's instructions. Sequences of the primers used are listed in **Supplementary File 1F** and the *Key Resource Table*. RT-qPCR data were normalized to the expression of the selected housekeeping gene *GUSB* (ENSG00000169919). CT values were normalized to *GUSB* by subtracting the CT mean of *GUSB* (measured in duplo) from the CT mean of the target mRNA (e.g., *RUNX3*) =  $\Delta CT$ . The

fold change (FC) of each sample was calculated compared to  $\Delta Ct$  of the medium control using the formula  $FC = 2^{-\Delta\Delta Ct}$ , where  $\Delta\Delta Ct = \Delta Ct_{\text{sample}} - \Delta Ct_{\text{reference}}$ .

#### *Flow cytometry of CD1c+ DC populations*

PBMC samples from the two cohorts (HC = 11 samples; AU = 9 samples; IU = 6 samples; BU = 11 samples) were randomly selected and measured by flow cytometry in batches of 9 to 10 mixed samples per run, divided over 4 days. Per batch, 10 million PBMCs per sample were quickly thawed, washed with ice cold PBS and stained with the antibody panel depicted in **Supplementary File 1C**. PBMCs were incubated with Fixable Viability Dye eF780 (eBioscience) at room temperature for 10 minutes. Cells were then plated in V-bottomed plates (Greiner Bio-one), washed with PBS and incubated for 30 minutes at 4°C in the dark with Brilliant Stain Buffer (BD) and the fluorescently-conjugated antibodies. Next, the cells were washed and taken up in the FACS buffer. Flow cytometric analyses were performed on the BD FACSAria™ III sorter. Manual gating of data was done using *FlowJo* software (TreeStar inc. San Carlos, CA, USA). FlowSOM v1.18.0 analysis was done as described previously (27). Lineage- (negative for CD3/CD56/CD19) HLA-DR+ data were transformed using the *logicleTransform* function of the *flowCore* v1.52.1 R package, using default parameters (28). The SOM was trained for a 7x7 grid (49 clusters) with 2000 iterations. Consensus hierarchical clustering was used to annotate clusters, based on the *ConsensusClusterPlus* v1.50.0 R package (29). Principal component analysis (PCA) analysis was done on normalized expression data from flowSOM using the *factoextra* v 1.0.7.999 R package.

#### *RNA isolation and RNA sequencing*

Total RNA from CD1c+ DC cell lysates from patients and controls was isolated using the AllPrep Universal Kit (Qiagen) on the QIAcube (Qiagen) according to the manufacturer's instructions. For cohort I, RNA-seq libraries were generated by *GenomeScan* (Leiden, the

Netherlands) with the TruSeq RNAseq RNA Library Prep Kit (Illumina Inc., Ipswich, MA, USA), and were sequenced using Illumina HiSeq 4000 generating ~20 million 150 bp paired end reads for each sample. Library preparation and Illumina sequencing was performed on samples of cohort II at BGI (Hong Kong). RNA-seq libraries were generated with the TruSeq RNAseq RNA Library Prep Kit (Illumina Inc., Ipswich, MA, USA) and were sequenced using Illumina NextSeq 500 generating approximately 20 million 100bp paired end reads for each sample.

#### *Power analysis*

We conducted power analysis using the PROPER R package v 1.22.0 (30) with 100 simulations of the *build-in* RNA-seq count data from antigen presenting (B) cells from a cohort of 41 individuals (i.e., large biological variation as expected in our study) (31). Simulation parameters used the default of 20,000 genes and an estimated 10% of genes being differentially expressed. We detected 0.8 power to detect differentially expressed genes ( $P<0.05$ ) at a  $\log_2(\text{fold change})>1$  for the smallest patient group (9 cases) and we considered the sample size reasonable for analysis.

#### *Differential gene expression and statistical analysis*

Quality check of the raw sequences was performed using the FastQC tool. Reads were aligned to the human genome (GRCh38 build 79) using STAR aligner (32) and the Python package HTSeq v0.6.1 was used to count the number of reads overlapping each annotated gene (33). We aligned the reads of the RNA sequencing data sets to 65,217 annotated *Ensemble Gene* IDs. Raw count data were fed into DESeq2 v1.30.1(34) to identify differentially expressed genes (DEGs) between the four disease groups (AU, IU, BU, HC). Using DESeq2, we modeled the biological variability and overdispersion in expression data following a negative binomial distribution. We used Wald's test in each disease group versus control pair-wise comparison and  $P$  values were corrected by the DESeq2 package using the Benjamini-Hochberg Procedure. We constructed co-expression gene networks with the

WGCNA v 1.70-3 R package (35) using the cumulative uveitis-associated genes from all pairwise comparisons and a soft power of 5. Module membership (MM) represents the intramodular connectivity of genes in a gene module. Gene Significance (GS>0.25) indicates a strong correlation between genes and non-infectious uveitis, whereas MM (MM>0.8) indicates a strong correlation with the *EigenGene* value of the modules. We calculated the intersection between the modules constructed from the two cohorts and used Fisher's exact test to identify modules that exhibited significant overlap in genes. Gene expression data from *runx3*-knockout(KO) cDC2s, *notch2*-KO cDC2s, and "inflammatory" cDC2s were obtained from the NCBI Gene Expression Omnibus (accession numbers GSE48590 [2 wild-type [WT] CD11b+ESAM+ splenic cDC2s versus 2 CD11b+ESAM+ cDC2s from CD11c-DC-*Runx3* $\Delta$  mice], GSE119242 [2 untreated cDC2 versus untreated cDC2 from CD11c-Cre *notch2*f/f mice], GSE149619 [5 CD172+MAR1- cDC2s in mock condition vs 3 CD172+MAR1+ cDC2 in virus condition]) using GEO2R in the GEO database, which builds on the GEOquery v2.58.0 and limma R v 3.46 packages (36, 37). RNA-seq data from the mouse bone marrow stromal cell line OP9 expressing NOTCH ligand DLL1 (OP9-DLL1)-driven cDC2 cultures (GSE110577, [2 sorted CD11c+MHCII+B220-CD11b+ cDC2 from bone marrow cultures with FLT3L for 7 days vs 2 sorted CD11c+MHCII+B220-CD11b+ cDC2 from bone marrow cultures with FLT3L + OP9-DLL1 cells for 7 days]) were analyzed using DESeq2 and normalized count data plotted using the *plotCounts* function. RNA-seq count data from CD14+- DC3 subsets from patients with SLE and systemic sclerosis were obtained via GEO (accession number: GSE136731) (17) and differential expression analysis was conducted using DESeq2 v1.30.1. Gene set enrichment analysis was done using the fgsea R package v1.16.0 and data plotted using the *GSEA.barplot* function from the *PPInfer* v 1.16.0 R package (38). Gene sets for *runx3*-KO, *notch2*-KO, inflammatory cDC2s, and cDC2s from OP9-DLL1 bone marrow cultures were generated by taking the top or bottom percentiles of ranked [-log10(P)  $\geq$  sign(log2(fold change))] genes from each data set as indicated. Genes in the modules of interest that encode cell-surface proteins were identified according to *surfaceome* predictor SURFY (39);

### *Single cell-RNA seq analysis of aqueous humor.*

Single cell RNA-seq (scRNA-seq) data from aqueous humor of 4 HLA-B27-positive anterior uveitis (identical to the AU group in this study) patients were obtained via Gene Expression Omnibus (GEO) repository with the accession code GSE178833. Data was processed using the R package *Seurat* v4.1.0 (40) using R v4.0.3. We removed low-quality cells (<200 or >2500 genes and mitochondrial percentages <5%) and normalized the data using the *SCTtransform()* function accounting for mitochondrial percentage and cell cycle score (41). Dimensionality reduction for all cells was achieved by adapting the original UMAP coordinates for each barcode as reported by Kasper *et al* 2021 (see GSE178833). Data were subjected to *scGate* v1.0.0 (42) using *CLEC10A+* and *C5AR1* (CD88)- cells in our gating model to purify CD1c+ DCs in the scRNA seq dataset. Dimensionality reduction for CD1c+ DCs was conducted using the R package *Seurat*, and cells clustered using the *FindNeighbors* and *FindClusters* functions from *Seurat*. After clustering and visualization with UMAP, we used the *DotPlot* function from the *Seurat* package to visualize the average expression of genes in each cluster.

### *Data and Code Availability*

The data code (R markdown), bulk RNA-Seq datasets, flow cytometry dataset, and cytokine expression dataset described in this publication are available via <https://dataVERSE.nl/> doi: <https://doi.org/10.34894/9Q0FVO> and deposited in NCBI's Gene Expression Omnibus accessible through GEO Series accession numbers GSE195501 and GSE194060.

## **Results**

### *A CX3CR1 gene module is associated with non-infectious uveitis*

We characterized the transcriptome of primary CD1c+ DCs from patients with non-infectious uveitis (**Figure 1A**). RNA-seq analysis (RNA-seq) was performed on lineage (CD3-CD19-

CD56-CD14-) negative, and HLA-DR-positive, CD11c and CD1c-positive DCs purified from frozen PBMCs by flow cytometry from 36 patients with anterior (AU), intermediate (IU), or posterior non-infectious uveitis (BU) and healthy controls. A co-expression network was constructed using uveitis-associated genes identified by differential expression analyses ( $n = 2,016$  genes at  $P < 0.05$ , **Figure 1B**), which identified six modules, of which 3 were associated with non-infectious uveitis (*Gene Significance*  $> 0.25$ , **Figure 1C**). The blue module was most associated with non-infectious uveitis (**Figure 1C**). Based on *Module Membership*, CX3CR1 was the top hub gene of the blue module (**Figure 1D, Supplementary File 1G**). Since CX3CR1 was previously associated with a distinct subset cDC2s that may also express CD14 (43, 44), we attempted to validate and expand the gene set associated with non-infectious uveitis by MACS-isolating CD1c+ DC cells from fresh blood of 28 patients and 14 healthy controls, followed by RNA-seq analysis of the highly purified CD1c+ DCs (median [interquartile range] % = 96[3]% pure, **Figure 1 - Figure Supplement 1**). We also constructed a co-expression network for uveitis-associated genes ( $n = 6,794$ ,  $P < 0.05$ ) in the second cohort (**Figure 1E**), which revealed 24 gene modules (**Supplementary File 1H**). Note that patient samples did not cluster according to clinical parameters of disease activity (e.g., cell grade in eye fluid, macular thickness) (**Figure 1 - Figure Supplement 2**). The 3 uveitis-associated modules in cohort I shared a significant number of co-expressed genes with one module in cohort II, the black module (**Figure 1F**). The black module was associated with non-infectious uveitis in cohort II (Gene Significance for uveitis  $> 0.25$ ) and CX3CR1 was also the hub gene for this module (Black Module Membership,  $P = 5.9 \times 10^{-22}$ ; **Supplementary File 1H, Figure 1G**). According to these findings, the overlapping disease-associated gene modules appear to represent a single gene module. In cohort I, the separation of genes into three modules was possibly due to low sensitivity to detect disease-associated genes with low expression, as replicated genes of the black module were typically higher expressed (**Figure 1 - Figure Supplement 3**). In total, we replicated 147 co-expressed genes between the two cohorts (which we will refer to as the “black module”), of which 94% also showed consistent direction of effect (e.g., upregulated in both cohorts) (**Figure 1H, Supplementary**

**File 1I).** The black module was enriched for the GO term “*positive regulation of cytokine production*” (GO:0001819,  $P_{adj} = 6.9 \times 10^{-5}$ ). In addition to CX3CR1, the black module comprised CD36, CCR2, TLR-6, -7, -8, CD180, and transcription factors RUNX3, IRF8, and NFKB1 (**Figure 2I**), but not CD14. In summary, these results show that a gene module characterized by CX3CR1 in blood CD1c+ DCs is associated with non-infectious uveitis.

***CX3CR1+ DC3 are diminished in peripheral blood of non-infectious uveitis patients***

Type I IFN cytokines promote differentiation of CD1c+ DCs (17,19), but patients with active non-infectious uveitis have reduced blood levels of type I IFN cytokines (21, 22). Assessment of the transcriptome of CD1c+ DCs from patients, found no enrichment for genes associated with murine type I IFN-dependent cDC2s (45) (**Figure 2A-B**). Furthermore, in CD1c+ DCs from healthy human donors, IFN-alpha did not induce downregulation of RUNX3 as observed in CD1c+ DCs from non-infectious uveitis patients (**Figure 2 - Figure Supplement 1A**). In contrast, the transcriptome of CD1c+ DCs from patients overlapped significantly with murine cDC2s knocked out for *Runx3*, or its upstream regulator *Notch2* (**Figure 2, Figure 2 - Figure Supplement 1B-C**) (46-48). Given that cDC2 subsets differ by their dependence on NOTCH signaling (46-49), we hypothesized that the transcriptomic signatures of the CD1c+ DC pool in patients might reflect changes in their proportions.

Therefore, we used flow cytometry analysis to identify CD1c+ DC clusters in peripheral blood mononuclear cells (PBMCs) samples from 26 cases and 11 controls. We designed a panel based on the black module (CX3CR1, CD36, CCR2, and CD180), other CD1c+ DC markers that were *not* in the black module (CD1c, CD11c, CD14, CD5, and CD163) (17, 50). FlowSOM (51) was used on HLA-DR+ and lineage (CD3/CD19/CD56)- PBMCs to cluster cells into a predetermined number of 49 clusters (7x7 grid) to facilitate detection of CD1c+ DC phenotypes in blood. The analysis with flowSOM clearly distinguished four CD1c+ DC clusters (cluster number 22, 37, 44, and 45) (**Figure 3A and Figure 3 – Supplement 1A and 1B**). We extracted the data for these four CD1c+ DC clusters and conducted *principal*

component analysis (PCA). The PCA biplot identified CD5 and CD163 as top loadings (**Figure 3 – Supplement 1C**), which defines the *DC2s* (cluster 45), CD5-CD163- DC3s (cluster 37), and CD5-CD163+ DC3s (cluster 22, and 44) (17) (**Figure 3B, 3C**). Among the identified clusters, we detected a significant reduction in the frequency of cluster 44 in patients compared to controls (Welch *t*-test,  $P = 0.03$ , **Figure 3D and Figure 3 – Supplement 1D**). Clusters 44 as well as cluster 22 were CD36 and CD14 positive, which indicates these clusters may represent CD14+ DC3s in human blood (17). However, cluster 44 had relatively higher levels of CX3CR1 than cluster 22. (**Figure 3E and 3F**). This suggests that DC3s may be phenotypically bifurcated by CX3CR1 independently of CD14. This is supported by weak correlation between *CD14* and *CX3CR1* in our RNA-seq data from bulk CD1c+ DCs (Pearson correlation coefficient = 0.35, **Figure 3 – Supplement 2A**). In addition, we sorted CD14-positive and CD14-negative fractions from CD1c+ DCs of six healthy donors (**Figure 3 - Figure Supplement 2B**) which showed no significant difference in expression levels for CX3CR1 (**Figure 3 - Figure Supplement 2C**). CX3CR1 levels were also not significantly different in sorted CD5-CD163+ CD14-positive and CD14-negative DC3s from patients with autoimmune diseases, further indicating that CX3CR1 expression in CD1c+ DCs may be independent from *CD14* expression in CD1c+ DCs (**Figure 3 - Figure Supplement 2D**).

We validated by manual gating that cluster 44 represents the CD36+CX3CR1+ fraction of CD1c+ DCs in peripheral blood (~25% of total CD1c+ DCs) (**Figure 3 - Figure Supplement 1E**). Comparison between patients and controls corroborated that the frequency of manual gated CD36+CX3CR1+ DC3s were decreased in the blood of non-infectious uveitis patients (Welch *t*-test,  $P = 0.029$ , **Figure 3G**). In detail, we show that CD14+ CD1c+ DCs double positive for CD36+ and CX3CR1 were significantly decreased ( $P = 0.026$ ), while CD14+CD1c+ DCs not positive for CX3CR1 were not ( $P = 0.43$ ) (**Figure 3G**). This supports that CX3CR1 discerns a phenotypic subpopulation of CD14+ DC3s (**Figure 3 - Figure Supplement 3**), that was diminished in the blood of patients with non-infectious uveitis.

*CX3CR1+DC3s can secrete pro-inflammatory cytokines upon stimulation.*

We compared the cytokine-producing abilities of CX3CR1+ DC3s to their negative counterparts since the gene module associated with CX3CR1 was enriched for genes involved in cytokine regulation. To this end, we freshly sorted primary human CD1c+ DC subsets based on the surface expression of CX3CR1 and CD36, of which double-positive and double-negative subsets could be sorted from the selected healthy subjects in sufficient numbers for analysis (**Figure 4 – Figure Supplement 1**). Since CD36 is involved in lipoteichoic acid (LTA) induced cytokine production (52), we overnight stimulated the CD1c+ subsets with LTA. Both subsets of CD1c+ DCs secreted IL-23 equally strongly (**Figure 4A**). To assess the secretome of the CD1c+ DC subsets in more detail, we profiled the supernatants of LTA-stimulated CD1c+ DC subsets for additional soluble immune mediators (**Supplementary File 1E**): The CD1c+ DC subsets could be distinguished based on the secreted protein profile (**Figure 4B**), of which the levels of TNF-alpha, IL-6, VEGF-A, and TNFR1 showed significant differences between the subsets (**Figure 4C**). These results show that CD1c+ DC subsets defined on the basis of surface co-expression of CD36 and CX3CR1 have the capacity to secrete pro-inflammatory mediators that participate in the pathophysiology of human non-infectious uveitis.

*CX3CR1+ DC3s are detectable in the inflamed eye during non-infectious uveitis.*

We speculated that CX3CR1+ DC3s are important in the disease mechanisms of uveitis and may be found at increased abundance in the eye during active uveitis. We used single-cell RNA sequencing data (scRNA-seq) of eye fluid biopsies of 4 noninfectious patients (53). Cells positive for the CD1c+ DC specific tissue-marker *CLEC10A* and negative for the monocyte marker *C5AR1* (CD88) (17, 20, 54) were used to identify CD1c+ DCs among other immune cells in the scRNA-seq data (**Figure 5A**). Unsupervised clustering identified three clusters (1, 2, and 3) of different cells within the CD1c+ DC population (**Figure 5B**). We identified that cluster 1 expressed the gene profile associated with CX3CR1+ DC3s, including relatively higher levels of CX3CR1, CD36, CCR2, and lower

levels of *RUNX3* compared to the other two CD1c+ DC clusters (**Figure 5C**), which is in line with the gene profile identified by our bulk RNA-seq analysis. In summary, we conclude that CD1c+ DCs with a gene expression profile similar to CX3CR1+ DC3s can be detected in the eyes of patients during active non-infectious uveitis.

## Discussion

In this study of non-infectious uveitis patients and controls, we identified and replicated a CX3CR1-associated gene module in CD1c+ DCs. We were able to track back the gene module to a CX3CR1+ DC3 subset that was diminished in peripheral blood of patients with non-infectious uveitis.

Preceding studies into human CD1c+ DCs revealed functionally distinct subsets termed “DC2” and “DC3”, with the DC3 showing both transcriptomic features reminiscent of cDC2s and monocytes - such as elevated *CD36* (16,17). DC3s also have distinct developmental pathways and transcriptional regulators compared to DC2 (16-18,20). Recently, Cytlak and associates revealed that lower expression of *IRF8* is linked to DC3 (18), a transcription factor that was also decreased in non-infectious uveitis. According to Brown et al. (43), CD1c+ DCs exhibit two subsets: cDC2A and cDC2B, whereas cDC2B exhibits higher expression of CX3CR1 and produces more TNF alpha and IL-6 than cDC2A upon stimulation. Accordingly, uveitis-associated CX3CR1+ DC3s described in this study exhibit similar phenotypical and functional features.

Dutertre and co-workers (17) showed that the phenotype of peripheral blood CD1c+ DCs can be further segregated according to the expression of CD163 and CD5, with “DC3” cells being characterized as CD5-CD163- or CD5-CD163+cells and “DC2” as CD5+CD163 cells. Our flow cytometry results confirm these findings, but we also show that CD5- CD163+ DC3s that

express CD14 are composed of CX3CR1-positive and CX3CR1-negative cells, of which the CX3CR1+ population is implicated in non-infectious uveitis.

Single-cell analysis supported that CD1c+ DCs in eye fluid of patients with noninfectious uveitis contain also a population that has a gene profile reminiscent of CX3CR1+ DC3s, with relatively higher levels of CX3CR1, CD36, CCR2, and lower levels of RUNX3. Patients with Systemic lupus erythematosus (SLE) display accumulation of CD14+DC3s in blood (17), while the population of CD14+DC3 cells was decreased in non-infectious uveitis patients. The differences between non-infectious uveitis and SLE may be related to distinct (i.e., opposite) immunopathological mechanisms; Type I interferons drive the maturation of cDC2s into “inflammatory cDC2s” (infcDC2s) (45) and can induce CD1c+ DCs to express a distinct set of surface-receptors (19). The type I interferon (IFN)- $\alpha$  drives immunopathology of SLE and administration of type I interferon therapy can induce *lupus-like* disease (23, 24). In favor of attributing the seemingly contrasting observations in blood CD1c+ subsets between SLE and non-infectious uveitis to distinct biology is the fact that, in contrast to elevated IFN- $\alpha$  in patients with SLE, in non-infectious uveitis patient’s disease exacerbations correlate with reduced blood type I IFN concentrations (21,22, 55). Despite the importance of type I IFN signaling on DC3s, our results suggest that DC3s are also dysregulated in conditions associated with decreased type I IFNs (21, 22), supporting additional pathways involved in DC3 regulation during chronic inflammation.

We showed that the gene module of CD1c+ DCs showed overlap with the gene signature of disrupted NOTCH2-signaling in cDC2s. *Notch2* signaling is mediated via the NF- $\kappa$ B family member *Relb* in murine cDC2s (56). NF- $\kappa$ B signaling via RelB suppresses type I Interferon signaling in cDC2s (57) while selective deletion of RelB in dendritic cells protects against autoimmunity (56, 58). It is tempting to speculate that the enrichment for NOTCH gene signatures implies altered NF- $\kappa$ B-Relb signaling in CD1c+ DCs, with a mechanism that varies between diseases mediated by type I IFNs (e.g., SLE) and type I IFN-negative diseases (e.g., uveitis). Although this warrants further investigation, some circumstantial evidence for this is the presence of NF- $\kappa$ B family members in the black module, such as *NFKB1* and

*NFKB1A*, the former associated previously with a CX3CR1+ cDC2s, while the latter can regulate *Relb* function in dendritic cells (59, 60). NF- $\kappa$ B-Relb signaling has been shown to suppress type I IFN via a histone demethylase encoded by *KDM4A* which was also in the black module (61). Regardless, the NF- $\kappa$ B pathways are regulated by the TNFR1, the main receptor for TNF alpha (62, 63). TNFR1 is expressed at the cell surface of cDC2s and its ectodomain cleaved by the NOTCH2-pathway regulator ADAM10 (63-65). We showed that both TNF alpha and sTNFR1 were higher in the secretome of activated CX3CR1+ DC3s. This is in agreement with previous studies on CD36+ DC3s (16) or CX3CR1+ cDC2B (T-bet-) that also produced higher levels of TNF-alpha (43). Interestingly, altered NF- $\kappa$ B signaling specifically in cDC2 is associated with clinical response to anti-TNF alpha therapy. (66). Anti-TNF therapy is effective for treatment of non-infectious uveitis (67), while anti-TNF therapy may also result in a dysregulated type I interferon response (68) indicating potentially cross regulatory mechanisms via NF- $\kappa$ B signaling and type I IFN signaling affecting cDC2s. More research is needed to resolve the regulatory mechanisms driving CD1+ DC changes in type I IFN-negative inflammation, including non-infectious uveitis. It is also possible that the change in CD1c+ DCs observed in this study results from cytokine-induced precursor emigration or differentiation.

Other disease modifying factors possibly affect the CD1c+ DC pool in uveitis patients. In mice, antibiotic treatment to experimentally disturb the microbiota affects a cDC2 subset phenotypically similar to CD1c+ DCs and decreases their frequency in the intestine of mice, which suggests microbiota-dependent signals involved in the maintenance of cDC2 subsets (43). This is especially interesting in light of growing evidence that microbiota dependent signals cause autoreactive T cells to trigger uveitis (69), which makes it tempting to speculate that gut-resident cDC2 subsets contribute to the activation of T cells in uveitis models. Dietary components can influence subsets of intestinal dendritic cells (70). Regardless, most likely, an ensemble of disease modulating factors is involved. For example, myeloid cytokines, such as GM-CSF, contribute to autoimmunity of the eye (71) and GM-CSF has been shown to stimulate the differentiation of human CD1c+ subset from

progenitors (20). However, GM-CSF signaling in conventional dendritic cells has a minor role in the inception of EAU (72). Our data supports that stimulation of CD1c+ subsets with GM-CSF or TLR ligands does not induce the transcriptional features of CD1c+ DCs during non-infectious uveitis, which is in line with previous observations that support that stimulated cDC2s do not convert from one into another subset (20).

Note that our results of a decreased subset of CD1c+ DCs in non-infectious uveitis are in contrast with previous flow cytometry reports in non-infectious uveitis (12-14). Chen and co-workers (14) reported an increase of CD1c+ myeloid dendritic cells in non-infectious uveitis. It is important to note, however, that their study did not include the DC marker CD11c, thereby including CD1c+CD11c- populations that do not cluster phenotypically with CD1c+ (CD11c+) DCs (e.g., *cluster 46*, see **Figure 3 - Figure Supplement 1A**), which may explain the differences compared to our study.

Better understanding of the changes in the CD1c+ DC pool during human non-infectious uveitis will help develop strategies to pharmacologically influence putative disease pathways involved at an early disease stage, which may lay the foundation for the design of effective strategies to halt progress towards severe visual complications or blindness. Perhaps targeting CD1c+ DCs may be achieved by dietary (microbiome) strategies and provide relatively safe preventive strategies for noninfectious uveitis.

To conclude, we have found that peripheral blood CD1c+ DCs have a gene module linked to a CX3CR1-positive CD1c+ DC subset implicated in noninfectious uveitis.

## Supplementary Materials

### Figure Supplements

Supplementary File 1A-I

## References

1. Thorne JE, Suhler E, Skup M, Tari S, Macaulay D, Chao J, Ganguli A. Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis. *JAMA Ophthalmol.* 2016 Nov 1;134(11):1237-1245.
2. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. *Br J Ophthalmol.* 1996 Sep;80(9):844-8.
3. Lee RW, Nicholson LB, Sen HN, Chan CC, Wei L, Nussenblatt RB, Dick AD. Autoimmune and autoinflammatory mechanisms in uveitis. *Semin Immunopathol.* 2014 Sep;36(5):581-94.
4. Caspi RR. A look at autoimmunity and inflammation in the eye. *J Clin Invest.* 2010 Sep;120(9):3073-83.
5. Kuiper JJW, Venema WJ. HLA-A29 and Birdshot Uveitis: Further Down the Rabbit Hole. *Front Immunol.* 2020 Nov 11;11:599558.
6. Huang XF, Li Z, De Guzman E, et al. Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci. *Invest Ophthalmol Vis Sci.* 2020;61(6):3. doi:10.1167/iovs.61.6.3
7. Kuiper JJW, Setten JV, Devall M, Cretu-Stancu M, Hiddingh S, Ophoff RA, Missotten TOAR, Velthoven MV, Den Hollander AI, Hoyng CB, James E, Reeves E, Cordero-Coma M, Fonollosa A, Adán A, Martín J, Koeleman BPC, Boer JH, Pulit SL, Márquez A, Radstake TRDJ. Functionally distinct ERAP1 and ERAP2 are a hallmark of HLA-A29-(Birdshot) Uveitis. *Hum Mol Genet.* 2018 Dec 15;27(24):4333-4343. doi: 10.1093/hmg/ddy319. PMID: 30215709; PMCID: PMC6276832.
8. Márquez A, Cordero-Coma M, Martín-Villa JM, Gorroño-Echebarría MB, Blanco R, Díaz Valle D, Del Rio MJ, Blanco A, Olea JL, Cordero Y, Capella MJ, Díaz-Llopis M, Ortego-Centeno N, Ruiz-Arruza I, Llorenç V, Adán A, Fonollosa A, Ten Berge J, Atan D, Dick AD, De Boer JH, Kuiper J, Rothova A, Martín J. New insights into the genetic component of non-infectious uveitis through an Immunochip strategy. *J Med Genet.* 2017 Jan;54(1):38-46. doi: 10.1136/jmedgenet-2016-104144. Epub 2016 Sep 8. PMID: 27609017.
9. Chen M, Liang D, Zuo A, Shao H, Kaplan HJ, Sun D. An A2B Adenosine Receptor Agonist Promotes Th17 Autoimmune Responses in Experimental Autoimmune Uveitis (EAU) via Dendritic Cell Activation. *PLoS One.* 2015 Jul 6;10(7):e0132348.

10. Fu Q, Man X, Wang X, Song N, Li Y, Xue J, Sun Y, Lin W. CD83+ CCR7+ NK cells induced by interleukin 18 by dendritic cells promote experimental autoimmune uveitis. *J Cell Mol Med.* 2019 Mar;23(3):1827-1839.
11. Wang B, Tian Q, Guo D, Lin W, Xie X, Bi H. Activated  $\gamma\delta$  T Cells Promote Dendritic Cell Maturation and Exacerbate the Development of Experimental Autoimmune Uveitis (EAU) in Mice. *Immunol Invest.* 2021 Feb;50(2-3):164-183.
12. Chen P, Urzua CA, Knickelbein JE, Kim JS, Li Z, Hannes S, Kuo D, Chaigne-Delalande B, Armbrust K, Tucker W, Liu B, Agrón E, Sen HN, Nussenblatt RB. Elevated CD1c+ Myeloid Dendritic Cell Proportions Associate With Clinical Activity and Predict Disease Reactivation in Noninfectious Uveitis. *Invest Ophthalmol Vis Sci.* 2016 Apr;57(4):1765-72. doi: 10.1167/iovs.15-18357. PMID: 27070110; PMCID: PMC4849533.
13. Chen P, Denniston A, Hannes S, Tucker W, Wei L, Liu B, Xiao T, Hirani S, Li Z, Jawad S, Si H, Lee RW, Sen HN, Nussenblatt RB. Increased CD1c+ mDC1 with mature phenotype regulated by TNF $\alpha$ -p38 MAPK in autoimmune ocular inflammatory disease. *Clin Immunol.* 2015 May;158(1):35-46. doi: 10.1016/j.clim.2015.03.002. Epub 2015 Mar 14. PMID: 25784146; PMCID: PMC4420697.
14. Chen P, Tucker W, Hannes S, Liu B, Si H, Gupta A, Lee RW, Sen HN, Nussenblatt RB. Levels of blood CD1c+ mDC1 and CD1chi mDC1 subpopulation reflect disease activity in noninfectious uveitis. *Invest Ophthalmol Vis Sci.* 2014 Dec 16;56(1):346-52.
15. O'Rourke M, Fearon U, Sweeney CM, Basdeo SA, Fletcher JM, Murphy CC, Canavan M. The pathogenic role of dendritic cells in non-infectious anterior uveitis. *Exp Eye Res.* 2018 Aug;173:121-128.
16. Villani AC, Satija R, Reynolds G, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. *Science.* 2017;356(6335):eaah4573. doi:10.1126/science.aah4573
17. Dutertre CA, Becht E, Irac SE, Khalilnezhad A, Narang V, Khalilnezhad S, Ng PY, van den Hoogen LL, Leong JY, Lee B, Chevrier M, Zhang XM, Yong PJA, Koh G, Lum J, Howland SW, Mok E, Chen J, Larbi A, Tan HKK, Lim TKH, Karagianni P, Tzioufas AG, Malleret B, Brody J, Albani S, van Roon J, Radstake T, Newell EW, Ginhoux F. Single-Cell Analysis of Human Mononuclear Phagocytes Reveals Subset-Defining Markers and Identifies Circulating Inflammatory Dendritic Cells. *Immunity.* 2019 Sep 17;51(3):573-589.e8. doi: 10.1016/j.jimmuni.2019.08.008. Epub 2019 Aug 29. PMID: 31474513.
18. Cytlak U, Resteu A, Pagan S, et al. Differential IRF8 Transcription Factor Requirement Defines Two Pathways of Dendritic Cell Development in Humans. *Immunity.* 2020;53(2):353-370.e8. doi:10.1016/j.jimmuni.2020.07.003
19. Girard M, Law JC, Edilova MI, Watts TH. Type I interferons drive the maturation of human DC3s with a distinct costimulatory profile characterized by high GITRL. *Sci Immunol.* 2020 Nov 13;5(53):eabe0347.

20. Bourdely P, Anselmi G, Vaivode K, Ramos RN, Missolo-Koussou Y, Hidalgo S, Tosselo J, Nuñez N, Richer W, Vincent-Salomon A, Saxena A, Wood K, Lladser A, Piaggio E, Helft J, Guermonprez P. Transcriptional and Functional Analysis of CD1c+ Human Dendritic Cells Identifies a CD163+ Subset Priming CD8+CD103+ T Cells. *Immunity*. 2020 Aug 18;53(2):335-352.e8.
21. Wang W, Chong WP, Li C, Chen Z, Wu S, Zhou H, Wan Y, Chen W, Gery I, Liu Y, Caspi RR, Chen J. Type I Interferon Therapy Limits CNS Autoimmunity by Inhibiting CXCR3-Mediated Trafficking of Pathogenic Effector T Cells. *Cell Rep*. 2019 Jul 9;28(2):486-497.e4
22. Kuiper JJW, Verhagen FH, Hiddingh S, Wennink RAW, Hansen AM, Casey KA, Hoefer IE, Haitjema S, Drylewicz J, Yakin M, Sen HN, Radstake TRDJ, de Boer JH. A Network of Serum Proteins Predict the Need for Systemic Immunomodulatory Therapy at Diagnosis in Noninfectious Uveitis. *Ophthalmol Sci*. 2022 May 31;2(3):100175. doi: 10.1016/j.xops.2022.100175. PMID: 36245752; PMCID: PMC9559086.
23. Rönnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. *Ann Intern Med*. 1991 Aug 1;115(3):178-83.
24. Rönnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. *J Intern Med*. 1990 Mar;227(3):207-10.
25. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. *Am J Ophthalmol*. 2005 Sep;140(3):509-16.
26. Bakker DS, de Graaf M, Nierkens S, Delemarre EM, Knol E, van Wijk F, de Bruin-Weller MS, Drylewicz J, Thijs JL. Unraveling heterogeneity in pediatric atopic dermatitis: Identification of serum biomarker based patient clusters. *J Allergy Clin Immunol*. 2022 Jan;149(1):125-134. doi: 10.1016/j.jaci.2021.06.029. Epub 2021 Jul 6. PMID: 34237306.
27. Laban KG, Rijken R, Hiddingh S, Mertens JS, van der Veen RLP, Eenhorst CAE, Pandit A, Radstake TRDJ, de Boer JH, Kalmann R, Kuiper JJW. cDC2 and plasmacytoid dendritic cells diminish from tissues of patients with non-Hodgkin orbital lymphoma and idiopathic
28. Ellis B, Haaland P, Hahne F, Le Meur N, Gopalakrishnan N, Spidlen J, Jiang M, Finak G (2020). flowCore: flowCore: Basic structures for flow cytometry data. R package version 2.2.0.
29. Wilkerson, D. M, Hayes, Neil D (2010). "ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking." *Bioinformatics*, 26(12), 1572-1573.
30. Wu H, Wang C, Wu Z. PROPER: comprehensive power evaluation for differential expression using RNA-seq. *Bioinformatics*. 2015 Jan 15;31(2):233-41.
31. Cheung VG, Nayak RR, Wang IX, Elwyn S, Cousins SM, Morley M, Spielman RS. Polymorphic cis- and trans-regulation of human gene expression. *PLoS Biol*. 2010 Sep 14;8(9):e1000480.

32. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*. 2013 Jan 1;29(1):15-21.
33. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput sequencing data. *Bioinformatics*. 2015 Jan 15;31(2):166-9.
34. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 2014;15(12):550.
35. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. *BMC Bioinformatics*. 2008 Dec 29;9:559.
36. Davis S, Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. *Bioinformatics*. 2007 Jul 15;23(14):1846-7.
37. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* 2015 Apr 20;43(7):e47.
38. Jung D, Ge X (2020). PPIInfer: Inferring functionally related proteins using protein interaction networks. R package version 1.16.0.
39. Bausch-Fluck D, Goldmann U, Müller S, van Oostrum M, Müller M, Schubert OT, Wollscheid B. The in silico human surfaceome. *Proc Natl Acad Sci U S A.* 2018 Nov 13;115(46):E10988-E10997.
40. Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM 3rd, Hao Y, Stoeckius M, Smibert P, Satija R. Comprehensive Integration of Single-Cell Data. *Cell.* 2019 Jun 13;177(7):1888-1902.e21. doi: 10.1016/j.cell.2019.05.031. Epub 2019 Jun 6. PMID: 31178118; PMCID: PMC6687398.
41. Hafemeister C, Satija R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. *Genome Biol.* 2019 Dec 23;20(1):296. doi: 10.1186/s13059-019-1874-1. PMID: 31870423; PMCID: PMC6927181.
42. Andreatta M, Berenstein AJ, Carmona SJ. scGate: marker-based purification of cell types from heterogeneous single-cell RNA-seq datasets. *Bioinformatics*. 2022 Mar 8;38(9):2642–4. doi: 10.1093/bioinformatics/btac141. Epub ahead of print. PMID: 35258562; PMCID: PMC9048671.
43. Brown CC, Gudjonson H, Pritykin Y, Deep D, Lavallée VP, Mendoza A, Fromme R, Mazutis L, Ariyan C, Leslie C, Pe'er D, Rudensky AY. Transcriptional Basis of Mouse and Human Dendritic Cell Heterogeneity. *Cell.* 2019 Oct 31;179(4):846-863.e24.
44. Fujita K, Chakarov S, Kobayashi T, Sakamoto K, Voisin B, Duan K, Nakagawa T, Horiuchi K, Amagai M, Ginhoux F, Nagao K. Cell-autonomous FLT3L shedding via ADAM10 mediates conventional dendritic cell development in mouse spleen. *Proc Natl Acad Sci U S A.* 2019 Jul 16;116(29):14714-14723. doi: 10.1073/pnas.1818907116. Epub 2019 Jul 1. PMID: 31262819; PMCID: PMC6642353.
45. Bosteels C, Neyt K, Vanheerswynghels M, van Helden MJ, Sichien D, Debeuf N, De Prijck S, Bosteels V, Vandamme N, Martens L, Saeys Y, Louagie E, Lesage M, Williams DL, Tang SC, Mayer JU,

Ronchese F, Scott CL, Hammad H, Guilliams M, Lambrecht BN. Inflammatory Type 2 cDCs Acquire Features of cDC1s and Macrophages to Orchestrate Immunity to Respiratory Virus Infection. *Immunity*. 2020 Jun 16;52(6):1039-1056.e9. doi: 10.1016/j.jimmuni.2020.04.005. Epub 2020 May 8. PMID: 32392463; PMCID: PMC7207120.

46. Lewis KL, Caton ML, Bogunovic M, Greter M, Grajkowska LT, Ng D, Klinakis A, Charo IF, Jung S, Gommerman JL, Ivanov II, Liu K, Merad M, Reizis B. Notch2 receptor signaling controls functional differentiation of dendritic cells in the spleen and intestine. *Immunity*. 2011 Nov 23;35(5):780-91. doi: 10.1016/j.jimmuni.2011.08.013. Epub 2011 Oct 20. PMID: 22018469; PMCID: PMC3225703.

47. Fasnacht N, Huang HY, Koch U, Favre S, Auderset F, Chai Q, Onder L, Kallert S, Pinschewer DD, MacDonald HR, Tacchini-Cottier F, Ludewig B, Luther SA, Radtke F. Specific fibroblastic niches in secondary lymphoid organs orchestrate distinct Notch-regulated immune responses. *J Exp Med*. 2014 Oct 20;211(11):2265-79. doi: 10.1084/jem.20132528. Epub 2014 Oct 13. PMID: 25311507; PMCID: PMC4203954.

48. Briseño CG, Satpathy AT, Davidson JT 4th, Ferris ST, Durai V, Bagadia P, O'Connor KW, Theisen DJ, Murphy TL, Murphy KM. Notch2-dependent DC2s mediate splenic germinal center responses. *Proc Natl Acad Sci U S A*. 2018 Oct 16;115(42):10726-10731.

49. Kirkling ME, Cytlak U, Lau CM, Lewis KL, Resteu A, Khodadadi-Jamayran A, Siebel CW, Salmon H, Merad M, Tsirigos A, Collin M, Bigley V, Reizis B. Notch Signaling Facilitates In Vitro Generation of Cross-Presenting Classical Dendritic Cells. *Cell Rep*. 2018.

50. Korenfeld D, Gorvel L, Munk A, Man J, Schaffer A, Tung T, Mann C, Klechevsky E. A type of human skin dendritic cell marked by CD5 is associated with the development of inflammatory skin disease. *JCI Insight*. 2017 Sep 21;2(18):e96101. doi: 10.1172/jci.insight.96101. PMID: 28931765; PMCID: PMC5621884.

51. Van Gassen S, Callebaut B, Van Helden MJ, Lambrecht BN, Demeester P, Dhaene T, Saeys Y. FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data. *Cytometry A*. 2015 Jul;87(7):636-45.

52. Jimenez-Dalmaroni MJ, Xiao N, Corper AL, Verdino P, Ainge GD, Larsen DS, Painter GF, Rudd PM, Dwek RA, Hoebe K, Beutler B, Wilson IA. Soluble CD36 ectodomain binds negatively charged diacylglycerol ligands and acts as a co-receptor for TLR2. *PLoS One*. 2009 Oct 22;4(10):e7411. doi: 10.1371/journal.pone.0007411. PMID: 19847289; PMCID: PMC2760212.

53. Kasper M, Heming M, Schafflick D, et al. Intraocular dendritic cells characterize HLA-B27-associated acute anterior uveitis. *eLife*. 2021;10:e67396. Published 2021 Nov 16. doi:10.7554/eLife.67396

54. Heger L, Balk S, Lühr JJ, Heidkamp GF, Lehmann CHK, Hatscher L, Purbojo A, Hartmann A, Garcia-Martin F, Nishimura SI, Cesnjevar R, Nimmerjahn F, Dudziak D. CLEC10A Is a Specific Marker for

Human CD1c+ Dendritic Cells and Enhances Their Toll-Like Receptor 7/8-Induced Cytokine Secretion. *Front Immunol.* 2018 Apr 27;9:744. doi: 10.3389/fimmu.2018.00744. PMID: 29755453; PMCID: PMC5934495.

55. Obermoser G, Pascual V. The interferon-alpha signature of systemic lupus erythematosus. *Lupus.* 2010 Aug;19(9):1012-9.

56. Diener N, Fontaine JF, Klein M, Hieronymus T, Wanke F, Kurschus FC, Ludwig A, Ware C, Saftig P, Bopp T, Clausen BE, Backer RA. Posttranslational modifications by ADAM10 shape myeloid antigen-presenting cell homeostasis in the splenic marginal zone. *Proc Natl Acad Sci U S A.* 2021 Sep 21;118(38):e2111234118. doi: 10.1073/pnas.2111234118. PMID: 34526403; PMCID: PMC8463803.

57. Saha I, Jaiswal H, Mishra R, Nel HJ, Schreuder J, Kaushik M, Singh Chauhan K, Singh Rawat B, Thomas R, Naik S, Kumar H, Tailor P. RelB suppresses type I Interferon signaling in dendritic cells. *Cell Immunol.* 2020 Mar;349:104043. doi: 10.1016/j.cellimm.2020.104043. Epub 2020 Jan 27. PMID: 32044112.

58. Andreas N, Potthast M, Geiselhöringer AL, Garg G, de Jong R, Riewaldt J, Russkamp D, Riemann M, Girard JP, Blank S, Kretschmer K, Schmidt-Weber C, Korn T, Weih F, Ohnmacht C. RelB Deficiency in Dendritic Cells Protects from Autoimmune Inflammation Due to Spontaneous Accumulation of Tissue T Regulatory Cells. *J Immunol.* 2019 Nov 15;203(10):2602-2613. doi: 10.4049/jimmunol.1801530. Epub 2019 Oct 2. PMID: 31578269; PMCID: PMC6826119.

59. Shih VF, Davis-Turak J, Macal M, Huang JQ, Ponomarenko J, Kearns JD, Yu T, Fagerlund R, Asagiri M, Zuniga EI, Hoffmann A. Control of RelB during dendritic cell activation integrates canonical and noncanonical NF-κB pathways. *Nat Immunol.* 2012 Dec;13(12):1162-70. doi: 10.1038/ni.2446. Epub 2012 Oct 21. PMID: 23086447; PMCID: PMC3634611.

60. Sun SC. Non-canonical NF-κB signaling pathway. *Cell Res.* 2011 Jan;21(1):71-85. doi: 10.1038/cr.2010.177. Epub 2010 Dec 21. PMID: 21173796; PMCID: PMC3193406.

61. Jin J, Hu H, Li HS, Yu J, Xiao Y, Brittain GC, Zou Q, Cheng X, Mallette FA, Watowich SS, Sun SC. Noncanonical NF-κB pathway controls the production of type I interferons in antiviral innate immunity. *Immunity.* 2014 Mar 20;40(3):342-54. doi: 10.1016/j.jimmuni.2014.02.006. PMID: 24656046; PMCID: PMC3983709.

62. Hayden MS, Ghosh S. Regulation of NF-κB by TNF family cytokines. *Semin Immunol.* 2014 Jun;26(3):253-66. doi: 10.1016/j.smim.2014.05.004. Epub 2014 Jun 21. PMID: 24958609; PMCID: PMC4156877.

63. Maney NJ, Reynolds G, Krippner-Heidenreich A, Hilkens CMU. Dendritic cell maturation and survival are differentially regulated by TNFR1 and TNFR2. *J Immunol.* 2014 Nov 15;193(10):4914-4923. doi: 10.4049/jimmunol.1302929. Epub 2014 Oct 6. PMID: 25288570; PMCID: PMC4896387.

64. Yang WS, Yu H, Kim JJ, Lee MJ, Park SK. Vitamin D-induced ectodomain shedding of TNF receptor 1 as a nongenomic action: D3 vs D2 derivatives. *J Steroid Biochem Mol Biol*. 2016 Jan;155(Pt A):18-25. doi: 10.1016/j.jsbmb.2015.09.019. Epub 2015 Sep 15. PMID: 26385608.
65. Iberg CA, Bourque J, Fallahee I, Son S, Hawiger D. TNF- $\alpha$  sculpts a maturation process in vivo by pruning tolerogenic dendritic cells. *Cell Rep*. 2022 Apr 12;39(2):110657. doi: 10.1016/j.celrep.2022.110657. PMID: 35417681; PMCID: PMC9113652.
66. Andres-Ejarque R, Ale HB, Grys K, Tosi I, Solanky S, Ainali C, Catak Z, Sreeneebus H, Saklatvala J, Dand N, de Rinaldis E, Chapman A, Nestle FO, Barnes MR, Warren RB, Reynolds NJ, Griffiths CEM, Barker JN, Smith CH, Di Meglio P; PSORT Consortium. Enhanced NF- $\kappa$ B signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. *Nat Commun*. 2021 Aug 6;12(1):4741. doi: 10.1038/s41467-021-25066-9. Erratum in: *Nat Commun*. 2021 Dec 16;12(1):7358. PMID: 34362923; PMCID: PMC8346545.
67. Touhami S, Diwo E, Sèvre P, Trad S, Bielefeld P, Sène D, Abad S, Brézin A, Quartier P, Koné Paut I, Weber M, Chiquet C, Errera MH, Sellam J, Cacoub P, Kaplanski G, Kodjikian L, Bodaghi B, Saadoun D. Expert opinion on the use of biological therapy in non-infectious uveitis. *Expert Opin Biol Ther*. 2019 May;19(5):477-490. doi: 10.1080/14712598.2019.1595578. Epub 2019 Apr 16. PMID: 30888881.
68. Conrad C, Di Domizio J, Mylonas A, Belkhodja C, Demaria O, Navarini AA, Lapointe AK, French LE, Vernez M, Gilliet M. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. *Nat Commun*. 2018 Jan 2;9(1):25. doi: 10.1038/s41467-017-02466-4. PMID: 29295985; PMCID: PMC5750213.
69. Horai R, Zárate-Bladés CR, Dillenburg-Pilla P, Chen J, Kielczewski JL, Silver PB, Jittayasothorn Y, Chan CC, Yamane H, Honda K, Caspi RR. Microbiota-Dependent Activation of an Autoreactive T Cell Receptor Provokes Autoimmunity in an Immunologically Privileged Site. *Immunity*. 2015 Aug 18;43(2):343-53. doi: 10.1016/j.immuni.2015.07.014. PMID: 26287682; PMCID: PMC4544742.
70. Ko HJ, Hong SW, Verma R, Jung J, Lee M, Kim N, Kim D, Surh CD, Kim KS, Rudra D, Im SH. Dietary Glucose Consumption Promotes RALDH Activity in Small Intestinal CD103+CD11b+ Dendritic Cells. *Front Immunol*. 2020 Aug 11;11:1897.
71. Croxford AL, Lanzinger M, Hartmann FJ, Schreiner B, Mair F, Pelczar P, Clausen BE, Jung S, Greter M, Becher B. The Cytokine GM-CSF Drives the Inflammatory Signature of CCR2+ Monocytes and Licenses Autoimmunity. *Immunity*. 2015 Sep 15;43(3):502-14.
72. Bing SJ, Silver PB, Jittayasothorn Y, Mattapallil MJ, Chan CC, Horai R, Caspi RR. Autoimmunity to neuroretina in the concurrent absence of IFN- $\gamma$  and IL-17A is mediated by a GM-CSF-driven eosinophilic inflammation. *J Autoimmun*. 2020 Nov;114:102507.

**Competing interests:** Authors declare that they have no competing interests

**Figure Legends:**

**Figure 1. A CX3CR1 gene module in CD1c+ Dendritic cells (CD1c+ DC) is associated with non-infectious uveitis.**

**A)** Study design. CD1c+ DCs were purified from blood and subjected to RNA sequencing. Co-expression network analysis was used to identify gene modules associated with uveitis. **B)** Principal component analysis (PCA) of the 2,016 uveitis-associated genes ( $P<0.05$ ) in 36 patients and control samples of cohort I **C)** Gene significance for uveitis for the gene modules identified by WGCNA. **D)** Module membership and Gene Significance for uveitis for the blue module of cohort I. **E)** PCA of the 6,794 uveitis-associated genes ( $P<0.05$ ) in 42 samples of cohort II. **F)** Cross-tabulation of the preservation of co-expressed genes between gene modules from cohort I and the black module from cohort II.  $P$  value is from Fisher's exact test. **G)** Same as in **D**, but for the black module of cohort II. **H)** Heatmaps of the 147 replicated co-expressed genes (rows) for samples (columns) from cohort I and II. The venn diagram shows the upregulated and downregulated genes (clusters shown in **H**). **I)** The (Log2) fold change in gene expression compared to healthy controls (x-axis) for all 147 replicated genes in patients with AU, IU, AND BU. Genes encoding surface proteins are indicated in black/grey. Key transcription factors are indicated in blue. AU; Anterior uveitis. IU; Intermediate uveitis. BU; Birdshot uveitis.

**Figure 2. The CX3CR1 gene module of CD1c+ DCs is enriched for NOTCH2-RUNX3 signaling.**

**A)** Volcano plot for the expression of genes of the black module in cDC2s of *runx3*-KO mice (GSE48590), *notch2*-KO mice (GSE119242), and type I IFN-dependent inflammatory [inf-]cDC2s (GSE149619). Up-regulated genes and down-regulated genes for each condition are indicated for each condition; grey dots denote the genes with no significant change in expression. **B)** Results from gene-set enrichment analysis for ranked transcriptomes (using 20,668 genes with  $\text{baseMean}>4$ ) for AU, IU, and BU patients. The top or bottom percentiles of the ranked  $[-\log_{10}(P) \otimes \text{sign}(\log_2(\text{FC}))]$  genes from *runx3*-KO cDC2s, *notch2*-KO cDC2s, and inf-cDC2s (see a) were used as gene sets.

Normalized enrichment scores (NES) and  $P$  values for each gene set is indicated. The dotted lines indicate  $P_{adj} = 0.05$ . AU = Anterior uveitis. IU = Intermediate uveitis. BU = Birdshot uveitis.

**Figure 3. CX3CR1+ DC3s are decreased in the blood of patients with non-infectious uveitis.** **A)** Heatmap of the surface protein expression for 49 flowSOM clusters of flow-cytometry analysis of PBMC samples from 26 patients and 11 controls. The four CD1c+ (CD3-CD19-CD56-HLA-DR+CD11c+) DC clusters identified (cluster 22, 37, 44, and 45) are shown (detailed heatmap in *Figure 3 – Supplement 1A*). **B)** Biplot of the normalized surface expression of CD5 and CD163 for the 4 CD1c+ DC clusters. **C)** Correlation plot between manually gated CD5-CD163- DC3s and CD5-CD163+ DC3s and DC3 flowSOM clusters 22, 37, and 44. **D)** The frequency of the 4 CD1c+DC flowSOM clusters as percentage of PBMCs.  $P$  values from Welch's *t*-test. **E)** PCA biplot of the DC3 clusters 22, 37, and 44. Loadings for PC1 and PC2 are shown on the right. **F)** Biplots of the normalized surface expression of CD36, CD14, and CX3CR1 in the DC3 clusters 22, 37, and 44. **G)** Manual gating strategy of CD1c+ DC subsets based on CD36 and CX3CR1 in PBMCs in uveitis cases and controls.  $P$  value from Welch's *t* test. Details on manual gating strategy: see *Figure 3 – Supplement 3*. Manual gating revealed that the CD14+ CD1c+ DCs (DC3s) can be further subdivided in a CX3CR1- and a CX3CR1+ population.

**Figure 4. CX3CR1+DC3s secrete high levels of cytokines implicated in non-infectious uveitis.** **A)** The CD1c+ DC cells were FACS sorted into CD36+CX3CR1+ and CD36-CX3CR1- CD1c+ DCs (Figure 4 – Supplement 1). The concentration of IL-23 (ELISA) in supernatants of 18h cultured primary human CD1c+ DC subsets cells stimulated with lipoteichoic acid (LTA). **B)** Heatmap of the levels (Z-score) of 16 detected proteins in supernatants of 18h cultured LTA-stimulated primary human CD1c+ DC subsets cells using an in-house multiplex Luminex assay (**Supplementary File 1E**). **C)** Scatter plots with overlay boxplot with mean and interquartile range of the levels of secreted TNF-alpha, Interleukin (IL)-6, VEGF-A, and TNFR1 from the multiplex protein data in *d*. ( $P_{adj} = P$  values from likelihood ratio test Bonferroni corrected for 16 detected proteins).

**Figure 5. Local CD1c+ DCs show a gene profile similar to CX3CR1+ DC3s in the inflamed eye during non-infectious uveitis** **A)** Single-cell RNA-sequencing (scRNAseq) analysis of eye fluid biopsies from non-infectious uveitis patients (GSE178833). UMAP projections of transcriptomic data from 492 CD1c+ DC cells (in red) identified by *scGate* analysis (using *CLEC10A*+ and *C5AR1*- cells as tissue markers for CD1c+ DCs). **B)** Unsupervised clustering of CD1c+ DCs identified in *a*. **C)** Dot plot showing average expression (color-scaled) of key marker genes of the black module and *CD14* in each cluster determined in *B*.

**Figure 1 – Supplement 1.** Purity check of cell fractions for RNA-sequencing in cohort I. Representative sample of flow cytometry gating of CD14+, CD19+, CD3+ and CD1c+ cell fractions in CD304-depleted, CD19-depleted and

CD1c+ enriched MACS fractions from fresh peripheral blood mononuclear cells. Manual gating data for each individual sample is available via: <https://doi.org/10.34894/9Q0FVO>. The percentage of cells positive for each marker on the group levels between the disease groups is indicated in the bottom.

**Figure 1 – Supplement 2.** Clinical parameters of disease activity in non-infectious uveitis in cohort I. **A-E**) A PCA plot based on the 678 differentially expressed genes ( $P_{adj}<0.05$ ). **(A)** the anterior chamber cell grade **(B)**, Vitreous fluid cell grade **(C)**, macular thickness in the left (OS) eye as determined by optical coherence tomography (OCT) **(D)**, and macular thickness in the right eye (OD) as determined by OCT **(E)** are shown.

**Figure 1 – Supplement 3.** Correlation plot of the mean normalized count (*baseMean* from *DESeq2*) of the black module genes from cohort 1 and the 147 overlapping genes in the blue, yellow, and green module in cohort 2.

**Figure 2 - Supplement 1.** **A)** Gene expression (mean [SEM]) for *RUNX3* and *CD36* in primary human CD1c+ DCs from healthy donors stimulated overnight. Each dot represents a single donor used in the experiment. **B)** Transcriptomic data of murine bone marrow progenitors cultured for 7 days with OP9 stromal cells that express the NOTCH2 ligand DLL1 or OP-9 cells without DLL1. This analysis revealed that notch2-controlled genes were enriched in the transcriptome of CD1c+ DCs of patients and that notch2-signaling associates with the expression of *cd36*, *ccr2*, and *cx3cr1* in cDC2s. Normalized counts (and adjusted  $P$  values from *DESeq2*) for *cx3cr1*, *ccr2*, *cd36*, and *runx3* from cDC2s (GSE110577) generated from murine bone marrow cells and OP-9 with (in blue) or without (in ochre) Notch ligand Delta-like 1 (DLL1). **C)** Gene set enrichment analysis using the top 1%, ( $n=201$ ) genes associated with the NOTCH-negative condition in *d* as the gene setR848 = Resiquimod, LTA = Lipoteichoic acid, LPS = Lipopolysaccharides, Pam3CSK4 = Pam3CysSerLys4, OxLDL = Oxidized low-density lipoprotein, IFN $\alpha$  = Interferon alpha, TGF $\beta$  = transforming growth factor beta. FLT3L = FMS-like tyrosine kinase 3 ligand, TNF $\alpha$  = tumor necrosis factor alpha, S100A12 = S100 calcium-binding protein A12, IL-4 = interleukin 4, GM-CSF = Granulocyte-macrophage colony-stimulating factor.

**Figure 3 – Supplement 1.** **A)** Heatmap of the surface protein expression for 49 flowSOM clusters of flow-cytometry analysis of PBMC samples from 26 patients and 11 controls. The four CD1c+ (CD3-CD19-CD56-HLA-DR+CD11c+) DC clusters identified (cluster 22, 37, 44, and 45) are highlighted. **B)** Biplot of the cell surface expression of CD1c and CD11c for the 49 flowSOM clusters in a. **C)** PCA biplot of the surface protein expression for clusters 22, 37, 44, and 45 identified in a. **D)** The proportion of the 4 CD1c+ DC clusters in the HLA-DR+Lin-(CD3-CD19-CD56) population in controls and patients. **E)** Manual gating strategy of CD1c+ DC subsets based on CD36 and CX3CR1 and the correlation between CD36+CX3CR1+ CD1c+ DCs and the flowSOM cluster 44.  $R =$

Spearman correlation. Gray area represents the 95% confidence interval of the linear regression line. **H)** The relative proportion of CD1c+ DC subsets based on CD36 and CX3CR1 in the HLA-DR+ Lin- gate.

**Figure 3 - Supplement 2.** **A)** Correlation plot of the gene expression levels of *CD14*, *CD36*, *CCR2*, *CX3CR1*, and the *EigenGene* value of the black module. **B)** Gating strategy to sort CD14+ and CD14- CD1c+ DCs from healthy donors. **C)** RT-qPCR results for a panel of genes of the black module in the sorted CD14+ and CD14- CD1c+ DC fractions in a. *Padj* = adjusted *P* values from *t.test* (Bonferroni) corrected for 7 genes. **D)** Volcano plot showing differential expression analysis for black module genes in CD14+ versus CD14- DC3s purified from SLE and SSc patients (GSE136731).

**Figure 3 – Supplement 3.** Representative sample of flow cytometry gating of CD14+ and CD14- fractions of CD1c+ DCs in peripheral blood for the panel used in Figure 3.


**Figure 4 – Supplement 1.** Representative examples of fluorescent-activated cell sorting (FACS) of CD36+CX3CR1+ DC3s and CD36-CX3CR1- CD1c+ DCs used for the analysis in Figure 4.








**Table 1.**


Cohort I	AU	IU	BU	HC	<i>P</i> value
<b>N</b>	10	5	8	13	Total=36
<b>Male / Female</b>	2/8	3/2	5/3	5/8	0.26*
<b>Age in years; mean <math>\pm</math> SD</b>	45 $\pm$ 16	30 $\pm$ 9	42 $\pm$ 10	42 $\pm$ 13	0.24***
<b>Disease duration in years; median (range)</b>	8.1 (0.2-22.3)	3.4 (0.4-14.1)	0.9 (0.2-19.9)	n.a.	0.36**
Cohort II	AU	IU	BU	HC	<i>P</i> value
N	9	9	10	14	Total=42
<b>Male / Female</b>	3/6	2/7	4/6	6/8	0.8790*
<b>Age in years; mean <math>\pm</math> SD</b>	47. $\pm$ 17	39 $\pm$ 14	52 $\pm$ 13	39 $\pm$ 10	0.06***
<b>Disease duration in years; median (range)</b>	5.8 (0.1-39.3)	3.7 (0.2-20.0)	1.3 (0.2-15.1)	n.a.	0.14**

**Table 1.** Characteristics of the patients and controls from cohort I and cohort II. Abbreviations: BU: Birdshot uveitis, AU: HLA-B27 associated anterior uveitis, HC: healthy control, IU: idiopathic intermediate uveitis, n.a.: not applicable, \* Fisher's exact test, \*\* ANOVA, \*\*\* Kruskal-Wallis.
















AU versus HC


- Black module genes (n=1236)
- Blue module genes (n=432)
- Yellow module genes (n=328)
- Green module genes (n=310)








**A****B****Genesets***runx3-KO cDC2* (GSE48590)DOWN Gene rank UP  
5th percentile 95th*notch2-KO cDC2* (GSE119242)DOWN Gene rank UP  
2th percentile 98th*inf-cDC2* (GSE149619)DOWN Gene rank UP  
2th percentile 98th







<i>runx3-KO</i>	<i>notch2-KO</i>	<i>inf-cDC2</i>
UP (pink)	UP (orange)	UP (dark purple)
DOWN (teal)	DOWN (light blue)	DOWN (yellow)















**A****B**


● NOTCH(-) culture  
● NOTCH(+) culture  
(GSE110577)




**C**




**A****B****C****D****E****F**





**A****B****C**



Tube: donor 1 Buffy

Population	#Events	%Parent	%Total
All Events	181,274	####	100.0
FCS/SSC	100,037	55.2	55.2
Single cells	94,165	94.1	51.9
Live cells	92,026	97.7	50.8
HLA-DR+ CD19- CD56-	20,907	22.7	11.5
CD1c+ CD11c+	1,135	5.4	0.6
CD36+ CX3CR1+ cDC	589	51.9	0.3
CD36- CX3CR1- cDC	345	30.4	0.2

